Journal of Neurology

, Volume 256, Issue 10, pp 1771–1772 | Cite as

Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis

Letter to the Editors

Notes

Conflict of interest statement

None.

References

  1. 1.
    Adelman B, Sandrock A, Panzara MA (2005) Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 353:432–433PubMedCrossRefGoogle Scholar
  2. 2.
    Bauer R, Humphries M, Fassler R, Winklmeier A, Craig SE, Bossehoff AK (2006) Regulation of integrin activity by MIA. J Biol Chem 281:11669–11677PubMedCrossRefGoogle Scholar
  3. 3.
    Davenpor RJ, Munday JR (2007) Alpha4-integrin antagonism—an effective approach for the treatment of inflammatory diseases? Drug Discov Today 12(13-14):569CrossRefGoogle Scholar
  4. 4.
  5. 5.
    Kedl RM, Mescher MF (1997) Migration and activation of antigen-specific CD8+ T cells upon in vivo stimulation with allogeneic tumour. J Immunol 159:650–663PubMedGoogle Scholar
  6. 6.
    Larouche N, Larouche K, Be’liveau A et al (1998) Transcriptional regulation of the alpha 4-integrin subunit gene in the metastatic spread of uveal melanoma. Anticancer Res 18(5a):3539–3547PubMedGoogle Scholar
  7. 7.
    Mullen JT, Vartanian TK, Atkins MB (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358(6):647–648PubMedCrossRefGoogle Scholar
  8. 8.
    Ogawa M, Tsutsui T, Zou JP et al (1997) Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumour sites following administration of interleukin 12. Cancer Res 57:2216–2222PubMedGoogle Scholar
  9. 9.
    Panzara MA, Bozic C, Sandrock AW (2008) More on melanoma with transdifferentiation. N Engl J Med 359(1):99PubMedCrossRefGoogle Scholar
  10. 10.
    Polman CH, O’Connor PW, Havrdova E et al (2006) A randomised placebo- controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med 354:899–910CrossRefGoogle Scholar
  11. 11.
    Qian F, Vaux DL, Weissman IL (1994) Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell 77(3):335–347PubMedCrossRefGoogle Scholar
  12. 12.
    Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923PubMedCrossRefGoogle Scholar
  13. 13.
    Stüve O, Marra CM, Bar-Or A et al (2006) Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63(10):1383–1387PubMedCrossRefGoogle Scholar
  14. 14.
    Ulrich C, Schmook T, Sachse MM et al (2004) Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 30:622–627PubMedCrossRefGoogle Scholar
  15. 15.
    Yang Y, Cardarelli PM, Lehnert K et al (1998) LPAM-1 (integrin alpha 4 beta 7)-ligand binding: overlapping binding sites recognizing VCAM-1, MAdCAM-1 and CS-1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides. Eur J Immunol 28(3):995–1004PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of NeurologyRoyal Hallamshire HospitalSheffieldUK

Personalised recommendations